Anti-GD2 chimeric antigen receptor T cell therapy - Sinobioway Cell TherapyAlternative Names: CAR-GD2-modified T cells - Sinobioway Cell Therapy; GD2-specific Chimeric Antigen Receptor-modified T Cells - Sinobioway Cell Therapy; GD2-targeted CAR-T cells - Sinobioway Cell Therapy
Latest Information Update: 06 Oct 2016
At a glance
- Originator Sinobioway Cell Therapy
- Class Antineoplastics; Cell therapies; Gene therapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Neuroblastoma
Most Recent Events
- 01 Sep 2016 Phase-I/II clinical trials in Neuroblastoma (Second-line therapy or greater, In children, In infants, In adolescents) in China (Parenteral) (NCT02919046)